A systemic review of the utility of antituberculosis therapy for presumed tuberculous uveitis.

A systemic review of the utility of antituberculosis therapy for presumed tuberculous uveitis.

Publication date: Jan 24, 2025

Uveitis presumed to be secondary to Mycobacterium tuberculosis is a rare but potentially blinding condition. Difficulty in making an accurate diagnosis and the low incidence of TB uveitis (TBU) contribute to the lack of evidence regarding the best management of this condition. This systematic review aims to analyse existing research to provide a summary of the literature regarding the utility of TB therapy for the management of TBU. This systematic review was prospectively registered on PROSPERO (PROSPERO 2021 CRD42021273379). We searched Medline, Embase and Central databases, and the search was done on 20th June 2023 with an updated literature search. We included 55 studies and found that the heterogeneity in the methodology of these studies precluded metanalysis, and a narrative analysis was undertaken. Risk of bias analysis was undertaken using the Newcastle-Ottawa scale. Key findings of this systematic review include multiple systemic biases in the available evidence, and general lack of control for confounding variables. This results in many unanswered questions regarding the utility of TB therapy for TBU and reinforces the need for more data in this area.

Open Access PDF

Concepts Keywords
Accurate Antitubercular Agents
Crd42021273379 Antitubercular Agents
June Extrapulmonary tuberculosis
Ottawa Humans
Tuberculosis Mycobacterium tuberculosis
Ocular tuberculosis
Ophthalmology
Tuberculosis
Tuberculosis
Tuberculosis, Ocular
Tuberculous uveitis
Uveitis

Semantics

Type Source Name
disease MESH uveitis
disease MESH Infectious Diseases
pathway REACTOME Reproduction
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH Ocular tuberculosis
disease MESH Extrapulmonary tuberculosis
disease MESH infection
drug DRUGBANK Trestolone
drug DRUGBANK Indoleacetic acid
disease MESH blindness
drug DRUGBANK Ademetionine
disease IDO blood
disease MESH endophthalmitis
disease MESH sarcoidosis
disease MESH spondyloarthropathies
disease IDO assay
drug DRUGBANK L-Phenylalanine
disease MESH Anterior uveitis
disease MESH granuloma
disease MESH Intermediate uveitis
disease MESH panuveitis
drug DRUGBANK D-Alanine
disease MESH abscess
disease MESH serpiginous choroiditis
disease MESH Retinitis
disease MESH retinal vasculitis
disease MESH optic neuritis
disease MESH scleritis
disease IDO pathogen
disease MESH posterior uveitis
disease IDO immunosuppression
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
drug DRUGBANK Methionine
drug DRUGBANK Trihexyphenidyl
disease IDO country
disease IDO site
disease MESH recurrences
drug DRUGBANK Coenzyme M
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
drug DRUGBANK Ethambutol
drug DRUGBANK Pyrazinamide
drug DRUGBANK Rifapentine
drug DRUGBANK Moxifloxacin
drug DRUGBANK Spinosad
disease IDO quality
disease IDO history
disease MESH inflammation
disease MESH Autoimmunity
drug DRUGBANK Gold
disease MESH Choroiditis
drug DRUGBANK L-Aspartic Acid
disease MESH Latent Tuberculosis
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH treatment failure
drug DRUGBANK Curcumin

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *